Risk factor
Very vulnerable to price shocks
Profitability factor
Very favourable analyst view
About
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on
Target Price
The average target price of CEVI.ST is 233 and suggests 56% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Buy
Sell